iTonic Holdings（ITOC）株式概要ヘルスケアソリューションプロバイダーであるiTonic Holdings Ltd.は、ブラキセラピーに使用される治療ソフトウェアと機器を開発・商品化している。 詳細ITOC ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ US市場と比較して、過去 3 か月間の株価の変動が非常に大きい過去5年間で収益は年間103.2%減少しました。 収益が 100 万ドル未満 ( $523K )+1 さらなるリスクすべてのリスクチェックを見るITOC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW471,153 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA471,153 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$0.292.5k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-5m703k2016201920222025202620282031Revenue US$523.0kEarnings US$66.1kAdvancedSet Fair ValueView all narrativesiTonic Holdings Ltd. 競合他社Firefly NeuroscienceSymbol: NasdaqCM:AIFFMarket cap: US$17.3mSafeSpace GlobalSymbol: OTCPK:SSGCMarket cap: US$18.1mDarioHealthSymbol: NasdaqCM:DRIOMarket cap: US$73.3mScienture HoldingsSymbol: NasdaqCM:SCNXMarket cap: US$18.3m価格と性能株価の高値、安値、推移の概要iTonic Holdings過去の株価現在の株価US$0.2952週高値US$1.1852週安値US$0.22ベータ01ヶ月の変化-11.13%3ヶ月変化-4.44%1年変化-56.45%3年間の変化n/a5年間の変化n/aIPOからの変化-92.31%最新ニュースお知らせ • Aug 06Itonic Holdings Ltd. Faces Shareholder Class Action LawsuitItonic Holdings Ltd. had a shareholder class action lawsuit filed against it. The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) PTHL was the subject of a market manipulation and fraudulent promotion scheme involving social-media based misinformation and impersonators posing as financial professionals; (2) PTHL’s public statements and risk disclosures omitted any mention of intention to use fraudulent trading or the realized risk of market manipulation used to drive iTonic’s stock price; (3) as a result, PTHL’s securities were at unique risk of extreme price volatility and trading halts triggered by the manipulation scheme; and (4) the Auditor Defendant and Underwriter Defendants had been involved with numerous foreign microcap public offerings that became targets of market manipulation schemes.お知らせ • Jul 15Itonic Holdings Ltd. Provides Update on Development of Ai-Powered Cloud Healthcare Platform for Nuclear Medicine Treatment PlanningiTonic Holdings Ltd. has announced continued progress in the development of its next-generation AI-enabled Treatment Planning System ("TPS") Cloud Platform through Mili (Jiangsu) Medical Technology Co. Ltd. The TPS Cloud Platform is being developed to transform traditional standalone treatment planning software into a cloud-based healthcare collaboration platform by integrating artificial intelligence ("AI"), medical data connectivity, automated quality control and workflow management capabilities. Mili Medical is upgrading its traditional standalone TPS software into a browser-based cloud platform, and is expected to enable healthcare professionals to access treatment planning capabilities across multiple locations and devices without relying on local software installation, if successfully completed and registered as required by applicable laws and regulations. The platform is being developed to incorporate AI algorithms designed to assist physicians with treatment planning workflows, including target area identification, organ segmentation and optimization recommendations, with the objective of improving efficiency and reducing operational complexity. These intended capabilities remain subject to further development, testing, clinical workflow validation and applicable regulatory review. The platform is being developed with automated quality management functions designed to support treatment verification, workflow monitoring, reporting and data traceability throughout the treatment process. The modular cloud architecture is designed to support future expansion into additional healthcare applications, including medical data management, supply chain coordination, research collaboration and intelligent healthcare services. As of the date of this announcement, the Company has completed significant development milestones, including: Core cloud architecture development; Browser-based TPS functionality development; Medical data sharing framework development; Initial AI model training; Quality control rule framework development. The Company is currently conducting internal testing, system optimization and clinical workflow validation. The platform has not been clinically validated for commercial use and has not received registration, clearance or approval from applicable regulators. The Company continues to evaluate collaboration opportunities with healthcare institutions to support future commercialization and market deployment. The TPS Cloud Platform is being developed by the Company to address these limitations by creating a centralized digital environment that connects physicians, medical departments and healthcare institutions through secure cloud-based workflows. The platform is expected to provide: Browser-based treatment planning access; Multi-location collaboration capabilities; Standardized medical data management; Automated workflow monitoring; Enhanced treatment planning efficiency. A core component of the platform is the integration of artificial intelligence technology designed to support clinical decision-making. The AI module is being developed to assist with: Automated identification and segmentation of treatment areas; Intelligent treatment plan recommendations; Continuous algorithm improvement through clinical data feedback; Reduction of repetitive manual processes. The Company is also developing a comprehensive quality control module intended to create a digital monitoring framework covering key treatment planning processes. Potential capabilities include: Treatment plan verification; Automated quality checks; Data recording and traceability; Exception alerts and reporting; Integration with existing hospital information systems. Following completion and validation of the core cloud platform, the Company plans to explore additional modular applications, including: Healthcare supply chain management: Digital tracking and management of medical supplies and equipment; Nuclear medicine management: Supporting lifecycle tracking of nuclear medicine materials and related records; Medical robotics integration: Potential connection between treatment planning systems and advanced medical equipment; Clinical research and patient management tools: Supporting research collaboration and long-term patient data management. The TPS Cloud Platform is expected to be regulated as medical device software in China and remains subject to applicable regulatory requirements, including registration testing, registration application and review procedures. The platform has not received regulatory approval or registration for commercialization, and there can be no assurance as to the timing or outcome of any required registration or approval process. Any delay in completing applicable regulatory procedures could delay the platform’s commercialization and market deployment.お知らせ • Jun 24Itonic Holdings Ltd Announces Board and Committee Changes, Effective June 18, 2026iTonic Holdings Ltd. announced that on June 18, 2026, Mr. Bin Wu tendered his resignation as an independent director of the Company, effective June 18, 2026. Mr. Wu's resignation was due to personal reasons, and not as a result of any disagreement between Mr. Wu and the Company on any matter relating to the Company's operations, policies or practices. Concurrently with the resignation of Mr. Wu, the board of directors of the Company appointed Kun Yang to succeed Mr. Wu as a new independent director of the Company on June 18, 2026. Kun Yang was also appointed to succeed Mr. Wu as a member of the Audit Committee, the Corporate Governance and Nominating Committee and the Compensation Committee of the Company and will replace Mr. Wu as the chair of the Corporate Governance and Nominating Committee. Kun Yang will become the new chair of the Corporate Governance and Nominating Committee. Kun Yang graduated from Hunan University of Technology and Business in July 2013 and obtained a bachelor's degree in accounting. In July 2021, Kun Yang obtained a master's degree in professional accounting from Jinan University.New Risk • Jun 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 7x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 103% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (US$523k revenue). Minor Risk Market cap is less than US$100m (US$32.8m market cap).Reported Earnings • Apr 01Full year 2025 earnings released: US$0.32 loss per share (vs US$0.052 loss in FY 2024)Full year 2025 results: US$0.32 loss per share (further deteriorated from US$0.052 loss in FY 2024). Net loss: US$5.10m (loss widened US$4.44m from FY 2024).お知らせ • Mar 25iTonic Holdings Ltd. announced that it expects to receive $20 million in fundingiTonic Holdings Ltd. announced that it has entered into a private placement subscription agreement with certain investors for a private placement offering of 100,000,000 Class A ordinary shares of par value $0.0001 per share at an issue price of $0.20 per Class A Ordinary Share for gross proceeds of $20,000,000 on March 23, 2026. The Private Placement is expected to close in April 2026, subject to satisfaction or waiver of the condition's precedent set forth in the Subscription Agreement. The Class A Ordinary Shares issued in the Private Placement are subject to a six-month lock-up period from the date of issuance.最新情報をもっと見るRecent updatesお知らせ • Aug 06Itonic Holdings Ltd. Faces Shareholder Class Action LawsuitItonic Holdings Ltd. had a shareholder class action lawsuit filed against it. The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) PTHL was the subject of a market manipulation and fraudulent promotion scheme involving social-media based misinformation and impersonators posing as financial professionals; (2) PTHL’s public statements and risk disclosures omitted any mention of intention to use fraudulent trading or the realized risk of market manipulation used to drive iTonic’s stock price; (3) as a result, PTHL’s securities were at unique risk of extreme price volatility and trading halts triggered by the manipulation scheme; and (4) the Auditor Defendant and Underwriter Defendants had been involved with numerous foreign microcap public offerings that became targets of market manipulation schemes.お知らせ • Jul 15Itonic Holdings Ltd. Provides Update on Development of Ai-Powered Cloud Healthcare Platform for Nuclear Medicine Treatment PlanningiTonic Holdings Ltd. has announced continued progress in the development of its next-generation AI-enabled Treatment Planning System ("TPS") Cloud Platform through Mili (Jiangsu) Medical Technology Co. Ltd. The TPS Cloud Platform is being developed to transform traditional standalone treatment planning software into a cloud-based healthcare collaboration platform by integrating artificial intelligence ("AI"), medical data connectivity, automated quality control and workflow management capabilities. Mili Medical is upgrading its traditional standalone TPS software into a browser-based cloud platform, and is expected to enable healthcare professionals to access treatment planning capabilities across multiple locations and devices without relying on local software installation, if successfully completed and registered as required by applicable laws and regulations. The platform is being developed to incorporate AI algorithms designed to assist physicians with treatment planning workflows, including target area identification, organ segmentation and optimization recommendations, with the objective of improving efficiency and reducing operational complexity. These intended capabilities remain subject to further development, testing, clinical workflow validation and applicable regulatory review. The platform is being developed with automated quality management functions designed to support treatment verification, workflow monitoring, reporting and data traceability throughout the treatment process. The modular cloud architecture is designed to support future expansion into additional healthcare applications, including medical data management, supply chain coordination, research collaboration and intelligent healthcare services. As of the date of this announcement, the Company has completed significant development milestones, including: Core cloud architecture development; Browser-based TPS functionality development; Medical data sharing framework development; Initial AI model training; Quality control rule framework development. The Company is currently conducting internal testing, system optimization and clinical workflow validation. The platform has not been clinically validated for commercial use and has not received registration, clearance or approval from applicable regulators. The Company continues to evaluate collaboration opportunities with healthcare institutions to support future commercialization and market deployment. The TPS Cloud Platform is being developed by the Company to address these limitations by creating a centralized digital environment that connects physicians, medical departments and healthcare institutions through secure cloud-based workflows. The platform is expected to provide: Browser-based treatment planning access; Multi-location collaboration capabilities; Standardized medical data management; Automated workflow monitoring; Enhanced treatment planning efficiency. A core component of the platform is the integration of artificial intelligence technology designed to support clinical decision-making. The AI module is being developed to assist with: Automated identification and segmentation of treatment areas; Intelligent treatment plan recommendations; Continuous algorithm improvement through clinical data feedback; Reduction of repetitive manual processes. The Company is also developing a comprehensive quality control module intended to create a digital monitoring framework covering key treatment planning processes. Potential capabilities include: Treatment plan verification; Automated quality checks; Data recording and traceability; Exception alerts and reporting; Integration with existing hospital information systems. Following completion and validation of the core cloud platform, the Company plans to explore additional modular applications, including: Healthcare supply chain management: Digital tracking and management of medical supplies and equipment; Nuclear medicine management: Supporting lifecycle tracking of nuclear medicine materials and related records; Medical robotics integration: Potential connection between treatment planning systems and advanced medical equipment; Clinical research and patient management tools: Supporting research collaboration and long-term patient data management. The TPS Cloud Platform is expected to be regulated as medical device software in China and remains subject to applicable regulatory requirements, including registration testing, registration application and review procedures. The platform has not received regulatory approval or registration for commercialization, and there can be no assurance as to the timing or outcome of any required registration or approval process. Any delay in completing applicable regulatory procedures could delay the platform’s commercialization and market deployment.お知らせ • Jun 24Itonic Holdings Ltd Announces Board and Committee Changes, Effective June 18, 2026iTonic Holdings Ltd. announced that on June 18, 2026, Mr. Bin Wu tendered his resignation as an independent director of the Company, effective June 18, 2026. Mr. Wu's resignation was due to personal reasons, and not as a result of any disagreement between Mr. Wu and the Company on any matter relating to the Company's operations, policies or practices. Concurrently with the resignation of Mr. Wu, the board of directors of the Company appointed Kun Yang to succeed Mr. Wu as a new independent director of the Company on June 18, 2026. Kun Yang was also appointed to succeed Mr. Wu as a member of the Audit Committee, the Corporate Governance and Nominating Committee and the Compensation Committee of the Company and will replace Mr. Wu as the chair of the Corporate Governance and Nominating Committee. Kun Yang will become the new chair of the Corporate Governance and Nominating Committee. Kun Yang graduated from Hunan University of Technology and Business in July 2013 and obtained a bachelor's degree in accounting. In July 2021, Kun Yang obtained a master's degree in professional accounting from Jinan University.New Risk • Jun 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 7x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 103% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (US$523k revenue). Minor Risk Market cap is less than US$100m (US$32.8m market cap).Reported Earnings • Apr 01Full year 2025 earnings released: US$0.32 loss per share (vs US$0.052 loss in FY 2024)Full year 2025 results: US$0.32 loss per share (further deteriorated from US$0.052 loss in FY 2024). Net loss: US$5.10m (loss widened US$4.44m from FY 2024).お知らせ • Mar 25iTonic Holdings Ltd. announced that it expects to receive $20 million in fundingiTonic Holdings Ltd. announced that it has entered into a private placement subscription agreement with certain investors for a private placement offering of 100,000,000 Class A ordinary shares of par value $0.0001 per share at an issue price of $0.20 per Class A Ordinary Share for gross proceeds of $20,000,000 on March 23, 2026. The Private Placement is expected to close in April 2026, subject to satisfaction or waiver of the condition's precedent set forth in the Subscription Agreement. The Class A Ordinary Shares issued in the Private Placement are subject to a six-month lock-up period from the date of issuance.Board Change • Feb 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Pengfei Zhang is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Jan 27iTonic Holdings Ltd. Announces Directorate and Committee Changes Effective January 22, 2026iTonic Holdings Ltd. announced that on January 22, 2026, Mr. Yun Fai Wong tendered his resignation as an independent director of the Company, effective immediately, due to personal reasons. Concurrently with the resignation of Mr. Wong, the board of directors of the Company appointed Mr. Bin Wu to succeed Mr. Wong as a new independent director of the Company on January 22, 2026. Mr. Wu was also appointed to succeed Mr. Wong as a member of the Audit Committee, the Corporate Governance and Nominating Committee and the Compensation Committee of the Company and will replace Mr. Yun Fai Wong as the chair of the Corporate Governance and Nominating Committee. Mr. Bin Wu will become the new chair of the Corporate Governance and Nominating Committee. Mr. Wu graduated from Wuhan University in July 1987 and obtained a Master of Business Administration from Duke University. The Company believes that Mr. Bin Wu qualifies as an independent director of the Company in accordance with Nasdaq Listing Rules and regulations of the Securities and Exchange Commission.New Risk • Jan 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 31% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.4m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 113% per year over the past 5 years. Revenue is less than US$1m (US$305k revenue). Market cap is less than US$10m (US$7.50m market cap). Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding).Reported Earnings • Dec 18First half 2025 earnings released: US$0.14 loss per share (vs US$0.024 loss in 1H 2024)First half 2025 results: US$0.14 loss per share (further deteriorated from US$0.024 loss in 1H 2024). Net loss: US$2.04m (loss widened US$1.75m from 1H 2024).New Risk • Dec 11New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.40m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 29% over the past year. Revenue is less than US$1m (US$448k revenue). Market cap is less than US$10m (US$9.40m market cap). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Shareholders have been diluted in the past year (20% increase in shares outstanding).Board Change • Dec 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Pengfei Zhang is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Nov 27Pheton Holdings Ltd, Annual General Meeting, Dec 19, 2025Pheton Holdings Ltd, Annual General Meeting, Dec 19, 2025, at 10:00 China Standard Time. Location: the executive centre - china resources tower no., 2666 south keyuan road, nanshan district, shenzhen, ChinaNew Risk • Oct 06New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (33% average weekly change). Revenue has declined by 29% over the past year. Shareholders have been substantially diluted in the past year (73% increase in shares outstanding). Revenue is less than US$1m (US$448k revenue). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (US$19.5m market cap).New Risk • Sep 10New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 73% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (33% average weekly change). Revenue has declined by 29% over the past year. Shareholders have been substantially diluted in the past year (73% increase in shares outstanding). Revenue is less than US$1m (US$448k revenue). Minor Risk Market cap is less than US$100m (US$22.2m market cap).New Risk • Jul 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$23.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (36% average weekly change). Revenue has declined by 29% over the past year. Revenue is less than US$1m (US$448k revenue). Minor Risk Market cap is less than US$100m (US$23.5m market cap).Reported Earnings • Mar 21Full year 2024 earnings released: US$0.052 loss per share (vs US$0.02 loss in FY 2023)Full year 2024 results: US$0.052 loss per share (further deteriorated from US$0.02 loss in FY 2023). Net loss: US$660.6k (loss widened 174% from FY 2023).New Risk • Feb 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (US$572k revenue). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$37.9m market cap).Reported Earnings • Oct 18First half 2024 earnings released: US$0.024 loss per share (vs US$0.007 loss in 1H 2023)First half 2024 results: US$0.024 loss per share (further deteriorated from US$0.007 loss in 1H 2023). Revenue: US$210.5k (down 21% from 1H 2023). Net loss: US$285.1k (loss widened 241% from 1H 2023).お知らせ • Sep 06Pheton Holdings Ltd has completed an IPO in the amount of $9 million.Pheton Holdings Ltd has completed an IPO in the amount of $9 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 2,250,000 Price\Range: $4 Discount Per Security: $0.28Board Change • Sep 03High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Pengfei Zhang is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.株主還元ITOCUS Healthcare ServicesUS 市場7D0.2%13.5%1.7%1Y-56.5%-18.9%20.0%株主還元を見る業界別リターン: ITOC過去 1 年間で-18.9 % の収益を上げたUS Healthcare Services業界を下回りました。リターン対市場: ITOCは、過去 1 年間で20 % のリターンを上げたUS市場を下回りました。価格変動Is ITOC's price volatile compared to industry and market?ITOC volatilityITOC Average Weekly Movement25.6%Healthcare Services Industry Average Movement10.1%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.1%安定した株価: ITOCの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: ITOCの weekly volatility ( 26% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19987Jianfei Zhangwww.ftzy.com.cnヘルスケア・ソリューション・プロバイダーであるiTonic Holdings Ltd.は、ブラキセラピーに使用される治療ソフトウェアと機器を開発・商品化している。同社が独自に開発した治療計画システムは、放射性粒子を体内に埋め込むことで、がん細胞を死滅させ、腫瘍を縮小させる放射線治療である。同社は、様々な悪性腫瘍を治療するための治療計画システムであるFTTPSを提供しており、標的体積、処方線量、リスクのある臓器を保護するための線量制限を決定し、がん患者に対するブラキセラピーの安全で効果的かつ正確な線量分布計画を作成することができる。同社は以前はPheton Holdings Ltd.として知られていたが、2026年1月にiTonic Holdings Ltd.に社名を変更した。 iTonic Holdings Ltd.は1998年に設立され、中国の北京に本社を置いている。 iTonic Holdings Ltd.はZJW（BVI）LTD.の子会社として運営されている。もっと見るiTonic Holdings Ltd. 基礎のまとめiTonic Holdings の収益と売上を時価総額と比較するとどうか。ITOC 基礎統計学時価総額US$36.05m収益（TTM）-US$5.10m売上高(TTM)US$523.03k65.0xP/Sレシオ-6.7xPER（株価収益率ITOC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ITOC 損益計算書（TTM）収益US$523.03k売上原価US$195.68k売上総利益US$327.35kその他の費用US$5.43m収益-US$5.10m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.044グロス・マージン62.59%純利益率-974.68%有利子負債／自己資本比率1.8%ITOC の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/13 09:15終値2026/08/13 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋iTonic Holdings Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Aug 06Itonic Holdings Ltd. Faces Shareholder Class Action LawsuitItonic Holdings Ltd. had a shareholder class action lawsuit filed against it. The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) PTHL was the subject of a market manipulation and fraudulent promotion scheme involving social-media based misinformation and impersonators posing as financial professionals; (2) PTHL’s public statements and risk disclosures omitted any mention of intention to use fraudulent trading or the realized risk of market manipulation used to drive iTonic’s stock price; (3) as a result, PTHL’s securities were at unique risk of extreme price volatility and trading halts triggered by the manipulation scheme; and (4) the Auditor Defendant and Underwriter Defendants had been involved with numerous foreign microcap public offerings that became targets of market manipulation schemes.
お知らせ • Jul 15Itonic Holdings Ltd. Provides Update on Development of Ai-Powered Cloud Healthcare Platform for Nuclear Medicine Treatment PlanningiTonic Holdings Ltd. has announced continued progress in the development of its next-generation AI-enabled Treatment Planning System ("TPS") Cloud Platform through Mili (Jiangsu) Medical Technology Co. Ltd. The TPS Cloud Platform is being developed to transform traditional standalone treatment planning software into a cloud-based healthcare collaboration platform by integrating artificial intelligence ("AI"), medical data connectivity, automated quality control and workflow management capabilities. Mili Medical is upgrading its traditional standalone TPS software into a browser-based cloud platform, and is expected to enable healthcare professionals to access treatment planning capabilities across multiple locations and devices without relying on local software installation, if successfully completed and registered as required by applicable laws and regulations. The platform is being developed to incorporate AI algorithms designed to assist physicians with treatment planning workflows, including target area identification, organ segmentation and optimization recommendations, with the objective of improving efficiency and reducing operational complexity. These intended capabilities remain subject to further development, testing, clinical workflow validation and applicable regulatory review. The platform is being developed with automated quality management functions designed to support treatment verification, workflow monitoring, reporting and data traceability throughout the treatment process. The modular cloud architecture is designed to support future expansion into additional healthcare applications, including medical data management, supply chain coordination, research collaboration and intelligent healthcare services. As of the date of this announcement, the Company has completed significant development milestones, including: Core cloud architecture development; Browser-based TPS functionality development; Medical data sharing framework development; Initial AI model training; Quality control rule framework development. The Company is currently conducting internal testing, system optimization and clinical workflow validation. The platform has not been clinically validated for commercial use and has not received registration, clearance or approval from applicable regulators. The Company continues to evaluate collaboration opportunities with healthcare institutions to support future commercialization and market deployment. The TPS Cloud Platform is being developed by the Company to address these limitations by creating a centralized digital environment that connects physicians, medical departments and healthcare institutions through secure cloud-based workflows. The platform is expected to provide: Browser-based treatment planning access; Multi-location collaboration capabilities; Standardized medical data management; Automated workflow monitoring; Enhanced treatment planning efficiency. A core component of the platform is the integration of artificial intelligence technology designed to support clinical decision-making. The AI module is being developed to assist with: Automated identification and segmentation of treatment areas; Intelligent treatment plan recommendations; Continuous algorithm improvement through clinical data feedback; Reduction of repetitive manual processes. The Company is also developing a comprehensive quality control module intended to create a digital monitoring framework covering key treatment planning processes. Potential capabilities include: Treatment plan verification; Automated quality checks; Data recording and traceability; Exception alerts and reporting; Integration with existing hospital information systems. Following completion and validation of the core cloud platform, the Company plans to explore additional modular applications, including: Healthcare supply chain management: Digital tracking and management of medical supplies and equipment; Nuclear medicine management: Supporting lifecycle tracking of nuclear medicine materials and related records; Medical robotics integration: Potential connection between treatment planning systems and advanced medical equipment; Clinical research and patient management tools: Supporting research collaboration and long-term patient data management. The TPS Cloud Platform is expected to be regulated as medical device software in China and remains subject to applicable regulatory requirements, including registration testing, registration application and review procedures. The platform has not received regulatory approval or registration for commercialization, and there can be no assurance as to the timing or outcome of any required registration or approval process. Any delay in completing applicable regulatory procedures could delay the platform’s commercialization and market deployment.
お知らせ • Jun 24Itonic Holdings Ltd Announces Board and Committee Changes, Effective June 18, 2026iTonic Holdings Ltd. announced that on June 18, 2026, Mr. Bin Wu tendered his resignation as an independent director of the Company, effective June 18, 2026. Mr. Wu's resignation was due to personal reasons, and not as a result of any disagreement between Mr. Wu and the Company on any matter relating to the Company's operations, policies or practices. Concurrently with the resignation of Mr. Wu, the board of directors of the Company appointed Kun Yang to succeed Mr. Wu as a new independent director of the Company on June 18, 2026. Kun Yang was also appointed to succeed Mr. Wu as a member of the Audit Committee, the Corporate Governance and Nominating Committee and the Compensation Committee of the Company and will replace Mr. Wu as the chair of the Corporate Governance and Nominating Committee. Kun Yang will become the new chair of the Corporate Governance and Nominating Committee. Kun Yang graduated from Hunan University of Technology and Business in July 2013 and obtained a bachelor's degree in accounting. In July 2021, Kun Yang obtained a master's degree in professional accounting from Jinan University.
New Risk • Jun 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 7x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 103% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (US$523k revenue). Minor Risk Market cap is less than US$100m (US$32.8m market cap).
Reported Earnings • Apr 01Full year 2025 earnings released: US$0.32 loss per share (vs US$0.052 loss in FY 2024)Full year 2025 results: US$0.32 loss per share (further deteriorated from US$0.052 loss in FY 2024). Net loss: US$5.10m (loss widened US$4.44m from FY 2024).
お知らせ • Mar 25iTonic Holdings Ltd. announced that it expects to receive $20 million in fundingiTonic Holdings Ltd. announced that it has entered into a private placement subscription agreement with certain investors for a private placement offering of 100,000,000 Class A ordinary shares of par value $0.0001 per share at an issue price of $0.20 per Class A Ordinary Share for gross proceeds of $20,000,000 on March 23, 2026. The Private Placement is expected to close in April 2026, subject to satisfaction or waiver of the condition's precedent set forth in the Subscription Agreement. The Class A Ordinary Shares issued in the Private Placement are subject to a six-month lock-up period from the date of issuance.
お知らせ • Aug 06Itonic Holdings Ltd. Faces Shareholder Class Action LawsuitItonic Holdings Ltd. had a shareholder class action lawsuit filed against it. The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) PTHL was the subject of a market manipulation and fraudulent promotion scheme involving social-media based misinformation and impersonators posing as financial professionals; (2) PTHL’s public statements and risk disclosures omitted any mention of intention to use fraudulent trading or the realized risk of market manipulation used to drive iTonic’s stock price; (3) as a result, PTHL’s securities were at unique risk of extreme price volatility and trading halts triggered by the manipulation scheme; and (4) the Auditor Defendant and Underwriter Defendants had been involved with numerous foreign microcap public offerings that became targets of market manipulation schemes.
お知らせ • Jul 15Itonic Holdings Ltd. Provides Update on Development of Ai-Powered Cloud Healthcare Platform for Nuclear Medicine Treatment PlanningiTonic Holdings Ltd. has announced continued progress in the development of its next-generation AI-enabled Treatment Planning System ("TPS") Cloud Platform through Mili (Jiangsu) Medical Technology Co. Ltd. The TPS Cloud Platform is being developed to transform traditional standalone treatment planning software into a cloud-based healthcare collaboration platform by integrating artificial intelligence ("AI"), medical data connectivity, automated quality control and workflow management capabilities. Mili Medical is upgrading its traditional standalone TPS software into a browser-based cloud platform, and is expected to enable healthcare professionals to access treatment planning capabilities across multiple locations and devices without relying on local software installation, if successfully completed and registered as required by applicable laws and regulations. The platform is being developed to incorporate AI algorithms designed to assist physicians with treatment planning workflows, including target area identification, organ segmentation and optimization recommendations, with the objective of improving efficiency and reducing operational complexity. These intended capabilities remain subject to further development, testing, clinical workflow validation and applicable regulatory review. The platform is being developed with automated quality management functions designed to support treatment verification, workflow monitoring, reporting and data traceability throughout the treatment process. The modular cloud architecture is designed to support future expansion into additional healthcare applications, including medical data management, supply chain coordination, research collaboration and intelligent healthcare services. As of the date of this announcement, the Company has completed significant development milestones, including: Core cloud architecture development; Browser-based TPS functionality development; Medical data sharing framework development; Initial AI model training; Quality control rule framework development. The Company is currently conducting internal testing, system optimization and clinical workflow validation. The platform has not been clinically validated for commercial use and has not received registration, clearance or approval from applicable regulators. The Company continues to evaluate collaboration opportunities with healthcare institutions to support future commercialization and market deployment. The TPS Cloud Platform is being developed by the Company to address these limitations by creating a centralized digital environment that connects physicians, medical departments and healthcare institutions through secure cloud-based workflows. The platform is expected to provide: Browser-based treatment planning access; Multi-location collaboration capabilities; Standardized medical data management; Automated workflow monitoring; Enhanced treatment planning efficiency. A core component of the platform is the integration of artificial intelligence technology designed to support clinical decision-making. The AI module is being developed to assist with: Automated identification and segmentation of treatment areas; Intelligent treatment plan recommendations; Continuous algorithm improvement through clinical data feedback; Reduction of repetitive manual processes. The Company is also developing a comprehensive quality control module intended to create a digital monitoring framework covering key treatment planning processes. Potential capabilities include: Treatment plan verification; Automated quality checks; Data recording and traceability; Exception alerts and reporting; Integration with existing hospital information systems. Following completion and validation of the core cloud platform, the Company plans to explore additional modular applications, including: Healthcare supply chain management: Digital tracking and management of medical supplies and equipment; Nuclear medicine management: Supporting lifecycle tracking of nuclear medicine materials and related records; Medical robotics integration: Potential connection between treatment planning systems and advanced medical equipment; Clinical research and patient management tools: Supporting research collaboration and long-term patient data management. The TPS Cloud Platform is expected to be regulated as medical device software in China and remains subject to applicable regulatory requirements, including registration testing, registration application and review procedures. The platform has not received regulatory approval or registration for commercialization, and there can be no assurance as to the timing or outcome of any required registration or approval process. Any delay in completing applicable regulatory procedures could delay the platform’s commercialization and market deployment.
お知らせ • Jun 24Itonic Holdings Ltd Announces Board and Committee Changes, Effective June 18, 2026iTonic Holdings Ltd. announced that on June 18, 2026, Mr. Bin Wu tendered his resignation as an independent director of the Company, effective June 18, 2026. Mr. Wu's resignation was due to personal reasons, and not as a result of any disagreement between Mr. Wu and the Company on any matter relating to the Company's operations, policies or practices. Concurrently with the resignation of Mr. Wu, the board of directors of the Company appointed Kun Yang to succeed Mr. Wu as a new independent director of the Company on June 18, 2026. Kun Yang was also appointed to succeed Mr. Wu as a member of the Audit Committee, the Corporate Governance and Nominating Committee and the Compensation Committee of the Company and will replace Mr. Wu as the chair of the Corporate Governance and Nominating Committee. Kun Yang will become the new chair of the Corporate Governance and Nominating Committee. Kun Yang graduated from Hunan University of Technology and Business in July 2013 and obtained a bachelor's degree in accounting. In July 2021, Kun Yang obtained a master's degree in professional accounting from Jinan University.
New Risk • Jun 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 7x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 103% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (US$523k revenue). Minor Risk Market cap is less than US$100m (US$32.8m market cap).
Reported Earnings • Apr 01Full year 2025 earnings released: US$0.32 loss per share (vs US$0.052 loss in FY 2024)Full year 2025 results: US$0.32 loss per share (further deteriorated from US$0.052 loss in FY 2024). Net loss: US$5.10m (loss widened US$4.44m from FY 2024).
お知らせ • Mar 25iTonic Holdings Ltd. announced that it expects to receive $20 million in fundingiTonic Holdings Ltd. announced that it has entered into a private placement subscription agreement with certain investors for a private placement offering of 100,000,000 Class A ordinary shares of par value $0.0001 per share at an issue price of $0.20 per Class A Ordinary Share for gross proceeds of $20,000,000 on March 23, 2026. The Private Placement is expected to close in April 2026, subject to satisfaction or waiver of the condition's precedent set forth in the Subscription Agreement. The Class A Ordinary Shares issued in the Private Placement are subject to a six-month lock-up period from the date of issuance.
Board Change • Feb 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Pengfei Zhang is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Jan 27iTonic Holdings Ltd. Announces Directorate and Committee Changes Effective January 22, 2026iTonic Holdings Ltd. announced that on January 22, 2026, Mr. Yun Fai Wong tendered his resignation as an independent director of the Company, effective immediately, due to personal reasons. Concurrently with the resignation of Mr. Wong, the board of directors of the Company appointed Mr. Bin Wu to succeed Mr. Wong as a new independent director of the Company on January 22, 2026. Mr. Wu was also appointed to succeed Mr. Wong as a member of the Audit Committee, the Corporate Governance and Nominating Committee and the Compensation Committee of the Company and will replace Mr. Yun Fai Wong as the chair of the Corporate Governance and Nominating Committee. Mr. Bin Wu will become the new chair of the Corporate Governance and Nominating Committee. Mr. Wu graduated from Wuhan University in July 1987 and obtained a Master of Business Administration from Duke University. The Company believes that Mr. Bin Wu qualifies as an independent director of the Company in accordance with Nasdaq Listing Rules and regulations of the Securities and Exchange Commission.
New Risk • Jan 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 31% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.4m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 113% per year over the past 5 years. Revenue is less than US$1m (US$305k revenue). Market cap is less than US$10m (US$7.50m market cap). Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding).
Reported Earnings • Dec 18First half 2025 earnings released: US$0.14 loss per share (vs US$0.024 loss in 1H 2024)First half 2025 results: US$0.14 loss per share (further deteriorated from US$0.024 loss in 1H 2024). Net loss: US$2.04m (loss widened US$1.75m from 1H 2024).
New Risk • Dec 11New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.40m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 29% over the past year. Revenue is less than US$1m (US$448k revenue). Market cap is less than US$10m (US$9.40m market cap). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Shareholders have been diluted in the past year (20% increase in shares outstanding).
Board Change • Dec 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Pengfei Zhang is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Nov 27Pheton Holdings Ltd, Annual General Meeting, Dec 19, 2025Pheton Holdings Ltd, Annual General Meeting, Dec 19, 2025, at 10:00 China Standard Time. Location: the executive centre - china resources tower no., 2666 south keyuan road, nanshan district, shenzhen, China
New Risk • Oct 06New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (33% average weekly change). Revenue has declined by 29% over the past year. Shareholders have been substantially diluted in the past year (73% increase in shares outstanding). Revenue is less than US$1m (US$448k revenue). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (US$19.5m market cap).
New Risk • Sep 10New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 73% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (33% average weekly change). Revenue has declined by 29% over the past year. Shareholders have been substantially diluted in the past year (73% increase in shares outstanding). Revenue is less than US$1m (US$448k revenue). Minor Risk Market cap is less than US$100m (US$22.2m market cap).
New Risk • Jul 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$23.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (36% average weekly change). Revenue has declined by 29% over the past year. Revenue is less than US$1m (US$448k revenue). Minor Risk Market cap is less than US$100m (US$23.5m market cap).
Reported Earnings • Mar 21Full year 2024 earnings released: US$0.052 loss per share (vs US$0.02 loss in FY 2023)Full year 2024 results: US$0.052 loss per share (further deteriorated from US$0.02 loss in FY 2023). Net loss: US$660.6k (loss widened 174% from FY 2023).
New Risk • Feb 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (US$572k revenue). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$37.9m market cap).
Reported Earnings • Oct 18First half 2024 earnings released: US$0.024 loss per share (vs US$0.007 loss in 1H 2023)First half 2024 results: US$0.024 loss per share (further deteriorated from US$0.007 loss in 1H 2023). Revenue: US$210.5k (down 21% from 1H 2023). Net loss: US$285.1k (loss widened 241% from 1H 2023).
お知らせ • Sep 06Pheton Holdings Ltd has completed an IPO in the amount of $9 million.Pheton Holdings Ltd has completed an IPO in the amount of $9 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 2,250,000 Price\Range: $4 Discount Per Security: $0.28
Board Change • Sep 03High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Pengfei Zhang is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
